Addex Therapeutics Ltd (ADXN.SW)
CHF 0.06
(-8.5%)
CHF 0.06
(-8.5%)
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2023 | 11.89 Million CHF | -47.03% |
| 2022 | 21.94 Million CHF | 19.11% |
| 2021 | 18.42 Million CHF | 16.19% |
| 2020 | 15.85 Million CHF | -8.7% |
| 2019 | 17.36 Million CHF | 132.54% |
| 2018 | 7.46 Million CHF | 130.86% |
| 2017 | 3.23 Million CHF | 2.98% |
| 2016 | 3.14 Million CHF | 18.95% |
| 2015 | 2.64 Million CHF | 46.99% |
| 2014 | 1.79 Million CHF | -87.57% |
| 2013 | 14.45 Million CHF | -46.47% |
| 2012 | 27.01 Million CHF | 364.76% |
| 2011 | 5.81 Million CHF | -83.66% |
| 2010 | 35.57 Million CHF | -25.2% |
| 2009 | 47.55 Million CHF | -7.97% |
| 2008 | 51.67 Million CHF | 35.61% |
| 2007 | 38.1 Million CHF | 47.96% |
| 2006 | 25.75 Million CHF | 0.0% |
| Year | Operating Expenses | Operating Expenses Growth |
|---|---|---|
| 2024 Q1 | 1.02 Million CHF | -63.4% |
| 2024 Q2 | 1.01 Million CHF | -0.54% |
| 2023 FY | 11.62 Million CHF | -47.03% |
| 2023 Q4 | 2.78 Million CHF | -6.49% |
| 2023 Q3 | 2.98 Million CHF | -6.21% |
| 2023 Q2 | 3.17 Million CHF | 9.56% |
| 2023 Q1 | 2.9 Million CHF | -29.1% |
| 2022 Q1 | 5.99 Million CHF | 28.39% |
| 2022 Q3 | 4.57 Million CHF | -37.1% |
| 2022 FY | 21.94 Million CHF | 19.11% |
| 2022 Q2 | 7.27 Million CHF | 21.26% |
| 2022 Q4 | 4.09 Million CHF | -10.61% |
| 2021 Q1 | 3.99 Million CHF | 7.78% |
| 2021 FY | 18.42 Million CHF | 16.19% |
| 2021 Q2 | 5.49 Million CHF | 37.75% |
| 2021 Q3 | 4.25 Million CHF | -22.57% |
| 2021 Q4 | 4.67 Million CHF | 9.76% |
| 2020 FY | 15.85 Million CHF | -8.7% |
| 2020 Q4 | 3.7 Million CHF | 17.96% |
| 2020 Q3 | 3.14 Million CHF | -18.11% |
| 2020 Q2 | 3.83 Million CHF | -25.92% |
| 2020 Q1 | 5.17 Million CHF | 17.78% |
| 2019 Q3 | 4.26 Million CHF | -12.68% |
| 2019 Q1 | 3.82 Million CHF | 185.08% |
| 2019 FY | 17.36 Million CHF | 132.54% |
| 2019 Q4 | 4.39 Million CHF | 3.07% |
| 2019 Q2 | 4.88 Million CHF | 27.69% |
| 2018 FY | 7.46 Million CHF | 130.86% |
| 2018 Q3 | 1.2 Million CHF | 174.65% |
| 2018 Q2 | 439.66 Thousand CHF | 0.0% |
| 2018 Q1 | 439.66 Thousand CHF | 208.38% |
| 2018 Q4 | 1.34 Million CHF | 11.1% |
| 2017 Q3 | 142.57 Thousand CHF | -67.08% |
| 2017 FY | 3.23 Million CHF | 2.98% |
| 2017 Q4 | 142.57 Thousand CHF | 0.0% |
| 2017 Q2 | 433.03 Thousand CHF | -0.0% |
| 2017 Q1 | 433.04 Thousand CHF | 125.01% |
| 2016 Q1 | 353.95 Thousand CHF | -32.58% |
| 2016 FY | 3.14 Million CHF | 18.95% |
| 2016 Q4 | 192.45 Thousand CHF | 0.0% |
| 2016 Q3 | 192.45 Thousand CHF | -45.63% |
| 2016 Q2 | 353.95 Thousand CHF | -0.0% |
| 2015 Q4 | 525.02 Thousand CHF | 0.0% |
| 2015 Q2 | 1 Million CHF | 0.0% |
| 2015 Q1 | 1 Million CHF | 311.8% |
| 2015 FY | 2.64 Million CHF | 46.99% |
| 2015 Q3 | 525.02 Thousand CHF | -47.86% |
| 2014 Q1 | 332.84 Thousand CHF | -64.94% |
| 2014 Q4 | 244.52 Thousand CHF | 0.0% |
| 2014 Q3 | 244.52 Thousand CHF | -26.54% |
| 2014 Q2 | 332.84 Thousand CHF | 0.0% |
| 2014 FY | 1.79 Million CHF | -87.57% |
| 2013 Q3 | 949.27 Thousand CHF | -60.16% |
| 2013 Q4 | 949.27 Thousand CHF | 0.0% |
| 2013 FY | 14.45 Million CHF | -46.47% |
| 2013 Q1 | 2.38 Million CHF | -2.07% |
| 2013 Q2 | 2.38 Million CHF | -0.0% |
| 2012 Q3 | 2.43 Million CHF | 0.0% |
| 2012 FY | 27.01 Million CHF | 364.76% |
| 2012 Q4 | 2.43 Million CHF | 0.0% |
| 2011 FY | 5.81 Million CHF | -83.66% |
| 2010 FY | 35.57 Million CHF | -25.2% |
| 2009 FY | 47.55 Million CHF | -7.97% |
| 2008 FY | 51.67 Million CHF | 35.61% |
| 2007 FY | 38.1 Million CHF | 47.96% |
| 2006 FY | 25.75 Million CHF | 0.0% |
| Name | Operating Expenses | Operating Expenses Difference |
|---|---|---|
| BB Biotech AG | -199.56 Million CHF | 105.96% |
| Basilea Pharmaceutica AG | 111.63 Million CHF | 89.345% |
| Evolva Holding SA | 89.66 Million CHF | 86.734% |
| Idorsia Ltd | 400.38 Million CHF | 97.029% |
| Kuros Biosciences AG | 36.21 Million CHF | 67.16% |
| Molecular Partners AG | 20.3 Million CHF | 41.413% |
| Relief Therapeutics Holding AG | 114.94 Million CHF | 89.652% |
| Santhera Pharmaceuticals Holding AG | 31.33 Million CHF | 62.042% |